Infertility Clinical Trial
This is an open-label, Phase 3, randomized, two arms, multicenter, prospective, experimental study of Folitime® (a new biosimilar formulation of r-hFSH, follitropin alfa) versus the original one (Gonal-f ®).
Follitropin alfa is a human follicle stimulating hormone (FSH) preparation of recombinant
DNA origin, which consists of two non-covalently linked, nonidentical glycoproteins
designated as the alfa- and beta-subunits. Similar to other glycoprotein hormones, FSH has a
high degree of heterogeneity due to differences in the amount and/or composition of the
carbohydrate residues, particularly sialic acid. FSH, the active component of r-hFSH is the
most important hormone responsible for follicular recruitment and development. In order to
obtain final maturation of the follicle and ovulation in the absence of an endogenous LH
surge, human chorionic gonadotropin (hCG) must be given following the administration of
r-hFSH when monitoring of the patient indicates that sufficient follicular development has
occurred.
Secondary endpoints to be measured by the study are
Efficacy
- Total dose of r-hFSH required,
- Number of days of r-hFSH stimulation
- Percentage of patients with need to increase or lower the dose of r-hFSH,
- Number of treatment cycle cancellations and their reason
- Fertilization rate
- Number of fertilized oocytes
- Number of good quality embryos
- Number of embryos transferred
- Implantation Rate
- Biochemical pregnancy
- Clinical pregnancy 10 weeks post embryo transfer
- Pregnancy outcome
Safety
Incidence of
- OHSS (and its severity)
- Local reactions (pain, bruising, redness, itching, swelling)
- Systemic drug adverse events
Tolerability
- Frequency of patients who withdraw the study drug due to lack of tolerance
- Frequency of patients who withdraw the study drug treatment due to any reason
- Patient Reported Pain: measured by a Patients Visual Analog Scale (VAS)
Immunogenicity Measurement of possible antibodies against exogenous r-hFSH will be
evaluated. Pharmacodynamics
- Number and size distribution of follicles during treatment
- Number and size distribution of follicles at the day of ovulation induction (uHCG)
- Number of follicles >14 mm on the day of hCG injection.
- Hormone parameters: serum levels of estradiol, luteinizing hormone and progesterone on
the day of hCG injection
- Metaphase II oocytes;
- Number of good quality oocytes
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A |